Reference health
Inebilizumab: First Approval
11/11 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
14 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 11 checked references that resolve
resolves10.1212/WNL.0000000000001729
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
resolves10.1212/NXI.0000000000000468
Mortality in neuromyelitis optica is strongly associated with African ancestry
resolves10.1007/s00415-017-8596-7
What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients
resolves10.3390/jcm5120107
Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies
resolves10.1124/jpet.110.168062
B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
resolves10.1177/1352458517740641
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
resolves10.1177/1352458515620934
Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
resolves10.1016/S0140-6736(19)31817-3
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
resolves10.1212/WNL.94.15_supplement.3998
Long-term Efficacy and Safety of Inebilizumab for Neuromyelitis Optica Spectrum Disorder in the Randomized, Double-blind N-MOmentum Study and Extension (3998)
The 14 references without a DOI — listed, not checked
no DOI — not checkedViela Bio. Viela Bio reports fourth quarter and full year 2019 financial results and business highlights [media release] 25 Mar 2020. https://vielabio.com.
no DOI — not checkedUS Food & Drug Administration. FDA approves new therapy for rare disease affecting optic nerve, spinal cord [media release] 11 June 2020. https://www.fda.gov.
no DOI — not checkedViela Bio. UpliznaTM (inebilizumab-cdon): US prescribing information. 2020. https://www.accessdata.fda.gov. Accessed 1 July 2020.
no DOI — not checkedMedImmune Inc. MedImmune completes cellective acquisition [media release] 17 Oct 2005. http://www.medimmune.com.
no DOI — not checkedAstraZeneca. AstraZeneca successfully completes acquisition of MedImmune [media release] 19 June 2007. http://www.astrazeneca.com.
no DOI — not checkedAstra Zeneca. MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics [media release] 28 Feb 2018. https://www.astrazeneca.com.
no DOI — not checkedViela Bio. Viela Bio spins out of MedImmune; launches with up to $250 Million Series A financing from investor consortium led by Boyu Capital, 6 Dimensions Capital, and Hillhouse Capital [media release] 28 Feb 2018. http://www.vielabio.com.
no DOI — not checkedViela Bio. Viela Bio enters strategic collaboration with Hansoh Pharma to develop and commercialize inebilizumab for autoimmune diseases and hematologic cancers in China [media release] 28 May 2019. http://www.vielabio.com.
no DOI — not checkedMitsubishi Tanabe Pharma Corporation. Mitsubishi Tanabe Pharma enters into a licensing agreement with Viela Bio for inebilizumab, a treatment agent for neuromyelitis optica spectrum disorder, in Japan and other Asian regions [media release] 9 Oct 2020. http://www.mt-pharma.co.jp.
no DOI — not checkedSchiopu E, Chatterjee S, Hsu V, et al. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 2016;18(131):1–14.
no DOI — not checkedBennett J, Aktas O, Rees W, et al. Characterization of B cell subset changes following treatment of neuromyelitis optica spectrum disorder with inebilizumab: results from the N-MOmentum study randomized control period [abstract no. 1097]. Mult Scler J. 2019;25(Suppl 2):590–2.
no DOI — not checkedMarignier R, Bennett JL, Kim HJ, et al. Inebilizumab prevents neuromyelitis optica spectrum disorder disability: outcomes from the N-MOmentum randomised, placebo-controlled, double-masked trial [abstract no. P1604]. Mult Scler J. 2019;25(Suppl 2):896–8.
no DOI — not checkedCree B, Bennett J, Kim HJ, et al. The N-MOmentum study—a randomised, placebo-controlled, double-blind trial of Inebilizumab for neuromyelitis optica spectrum disorder: randomised controlled period and open-label extension results [abstract no. 139]. Mult Scler J. 2019;25(Suppl 2):42–4.
no DOI — not checkedViela Bio. Viela Bio reports first quarter 2020 financial results and program highlights [media release] 13 May 2020. http://www.vielabio.com.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1007/s40265-020-01370-4"><img src="https://citestamp.com/citestamped/10.1007/s40265-020-01370-4/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1007/s40265-020-01370-4)